Malignant glioma drug discovery – targeting protein kinases

Bibliography

• CENTRAL BRAIN TUMOR REGISTRY OF THE UNITED STATES: Statistical report: Primary Brain Tumors in the United States, 1997-2001. Central brain tumor registry of the United States (CBTRUS), IL, USA (2005).
   Google Scholar
• KLEIHUES P, CAVENEE WK: World Health Organization Classification of Tumours: Pathology and Genetics: Tumours of the Nervous System, (2nd edn), WHO Publications Centre USA, Albany, 2000.
   Google Scholar
• DEANGELIS LM: Brain tumors. N. Engl. J. Med. (2001) 344:1140-123.
   PubMed Web of Science ®Google Scholar
• LACROIX M, ABI-SAID D, FOURNEY DR et al.: A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J. Neurosurg. (2001) 95(2):190-198.
   PubMed Web of Science ®Google Scholar
• STUPP R, MASON WP, VAN DEN BENT MJ et al.: Radiotherapy with concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. (2005) 352(10):987-996.
   PubMed Web of Science ®Google Scholar
• TAPHOORN MJ, STUPP R, COENS C et al.: Health-related quality of life in patients with glioblastoma: a randomized controlled trial. Lancet Oncol. (2005) 6(12):937-944.
   PubMed Web of Science ®Google Scholar
• SCOTT CB, SCARANTINO C, URTASUN R et al.: Validation and predictive power of Radiation Therapy Oncology Group (RTOG) recursive partitioning analysis classes for malignant glioma patients: a report using RTOG 90-06. Int. J. Radiat. Oncol. Biol. Phys. (1998) 40:51-55.
   PubMed Web of Science ®Google Scholar
• WONG ET, HESS KR, GLEASON MJ et al.: Outcomes and prognostic factors in recurrent glioma patients enrolled onto Phase II clinical trial. J. Clin. Oncol. (1999) 17:2572-2578.
   PubMed Web of Science ®Google Scholar
• HANAHAN D, WEINBERG R: The hallmarks of cancer. Cell (2000) 100:57-70.
   PubMed Web of Science ®Google Scholar
• SMITH JS, TACHIBANA I, PASSE SM et al.: PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme. J. Natl. Cancer Inst. (2001) 93(16):1246-1256.
   PubMed Web of Science ®Google Scholar
• DAI C, CELESTINO JC, OKADA Y, LOUIS DN, FULLER GN, HOLLAND EC: PDGF autocrine stimulation dedifferentiates cultured astrocytes and induces oligodendrogliomas and oligoastrocytomas from neural progenitors and astrocytes in vivo. Genes Dev. (2001) 15(15):1913-1925.
   PubMed Web of Science ®Google Scholar
• ROWINSKY, ERIC K: Signal events: cell signal transduction and its inhibition in cancer. Oncologist (2003) 8(Suppl. 3):5-17.
   PubMed Web of Science ®Google Scholar
• FELDKAMP MM, LAU N, GUHA A: Signal transduction pathways and their relevance in human astrocytomas. J. Neurooncol. (1997) 35(3):228-248.
   Google Scholar
• BLUME-JENSEN P, HUNTER T: Oncogenic kinase signaling. Nature (2001) 411:355-365.
   PubMed Web of Science ®Google Scholar
• COHEN P: Protein kinases, the major drug targets of the 21st century? Nat. Rev. Drug Discov. (2002) 1:309-316.
   PubMed Web of Science ®Google Scholar
• FUTREAL P, KASPRZYK A, BIRNEY E et al.: Cancer and genomics. Nature (2001) 409:850-852.
   PubMed Web of Science ®Google Scholar
• FABBRO D, RUETZ S, BUCHDUNGER E et al.: Protein kinases as targets for anticancer agents: from inhibitors to useful drugs. Pharmacol. Ther. (2002) 93:79-98.
   PubMed Web of Science ®Google Scholar
• ROBINSON DR, WU YM, LIN SF: The protein tyrosine kinase family of the human genome. Oncogene. (2000) 19(49):5548-5557.
   PubMed Web of Science ®Google Scholar
• SATHORNSUMETEE S, RICH JN: New treatment strategies for malignant gliomas. Expert Rev. Anti-Cancer Ther. (2006) 6(7):1-18.
   Web of Science ®Google Scholar
• CITRI A, YARDEN Y: EGF-ERBB signaling: towards the systems level. Nat. Rev. Mol. Cell Biol. (2006) 7(7):505-516.
   PubMed Web of Science ®Google Scholar
• CHU CT, EVERISS KD, WIKSTRAND CH et al.: Receptor dimerization is not a factor in the signaling activity of a transforming variant epidermal growth factor receptor (EGFRvIII). Biochem. J. (1997) 324(Pt 3):855-861.
   PubMed Web of Science ®Google Scholar
• ARTEAGA CL: The epidermal growth factor receptor: from mutant oncogene in nonhuman cancers to therapeutic target in human meoplasia. J. Clin. Oncol. (2001) 19:325-405.
   Web of Science ®Google Scholar
• RICH JN, REARDON DA, PEERY T et al.: Phase II trial of gefitinib in recurrent glioblastoma. J. Clin. Oncol. (2004) 22(1):133-142.
   PubMed Web of Science ®Google Scholar
• GALANIS E, BUCKNER JC, MAURER MJ et al.: Validation of neuroradiologic response assessment in gliomas: measurement by RECIST, two-dimensional, computer-assisted tumor area, and computer-assisted tumor volume methods. Neuro-oncol. (2006) 8(2):156-165.
   PubMed Web of Science ®Google Scholar
• PRADOS MD, LAMBORN KR, CHANG S et al.: Phase I study of erlotinib HCl alone and combined with temozolomide in patients with stable or recurrent malignant glioma. Neurooncol. (2006) 8:67-78.
   Google Scholar
• VOGELBAUM MA, PEEREBOOM D, STEVENS G, BARNETT G, BREWER C: Phase II trial of EGFR tyrosine kinase inhibitor erlotinib for single agent therapy of recurrent glioblastoma multiforme: interim results. Proc. Am. Soc. Clin. Oncol. (2004) 22:1558a.
   Google Scholar
• RAIZER JJ, ABREY LE, WEN P et al.: Phase II trial of erlotinib (OSI-779) in patients (pts) with recurrent malignant gliomas (MG) not on EIAEDs. Proc. Am. Soc. Clin. Oncol. (2004) 22:1502a.
   Google Scholar
• LYNCH TJ, BELL DW, SORDELLA R et al.: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. (2004) 350(21):2129-2139.
   PubMed Web of Science ®Google Scholar
• RICH JN, RASHEED BK, YAN H: EGFR mutations and sensitivity to gefitinib. N. Engl. J. Med. (2004) 351(12):1260-1261.
   PubMed Web of Science ®Google Scholar
• LASSMAN AB, ROSSI MR, RAIZER JJ et al.: Molecular study of malignant gliomas treated with epidermal growth factor receptor inhibitors: tissue analysis from North American Brain Tumor Consortium Trials 01-03 and 00-01. Clin. Cancer Res. (2005) 11(21):7841-7850.
   PubMed Web of Science ®Google Scholar
• MARIE Y, CARPENTIER AF, OMURO AM et al.: EGFR tyrosine kinase domain mutations in human gliomas. Neurology (2005) 64(8):1444-1445.
   PubMed Web of Science ®Google Scholar
• HAAS-KOGAN DA, PRADOS MD, TIHAN T et al.: Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib. J. Natl. Cancer Inst. (2005) 97:880-887.
   PubMed Web of Science ®Google Scholar
• MELLINGHOFF IK, WANG MY, VIVANCO I et al.: Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N. Engl. J. Med. (2005) 353:2012-2014.
   PubMed Web of Science ®Google Scholar
• ELLER JL, LONGO SL, HICKLIN DJ, CANUTE GW: Activity of anti-epidermal growth factor receptor monoclonal antibody C225 against glioblastoma multiforme. Neurosurgery. (2002) 51(4):1005-1013.
   PubMed Web of Science ®Google Scholar
• ELLER JL, LONGO SL, KYLE MM, BASSANO D, HICKLIN DJ, CANUTE GW: Anti-epidermal growth factor receptor monoclonal antibody cetuximab augments radiation effects in glioblastoma multiforme in vitro and in vivo. Neurosurgery (2005) 56(1):155-162.
   PubMed Web of Science ®Google Scholar
• SADONES J, CHASKIS E, JOOSENS EJ et al.: A stratified Phase II study of cetuximab for the treatment of recurrent glioblastoma multiforme: Preliminary results. Proc. Am. Soc. Clin. Oncol. (2006) 24:18S. Abstract 1558.
   Google Scholar
• JI H, ZHAO X, YUZA Y et al.: Epidermal growth factor receptor variant III mutations in lung tumorigenesis and sensitivity to tyrosine kinase inhibitors. Proc. Natl. Acad. Sci. USA (2006) 103(20):7817-7822.
   PubMed Web of Science ®Google Scholar
• ERLICHMAN C, HIDALGO M, BONI JP et al.: Phase I study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor, in patients with advanced solid tumors. J. Clin. Oncol. (2006) 24(15):2252-2260.
   PubMed Web of Science ®Google Scholar
• SHIH AH, HOLLAND EC: Platelet-derived growth factor (PDGF) and glial tumorigenesis. Cancer Lett. (2006) 232(2):139-147.
   PubMed Web of Science ®Google Scholar
• BUCGDUNGER E, CIOFFI CL, LAW N et al.: Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J. Pharmacol. Exp. Ther. (2000) 295(1):139-145.
   PubMed Web of Science ®Google Scholar
• SERVEDEI T, RICCARDI A, SANGUINETTI M et al.: Increased sensitivity to the platelet-derived growth factor (PDGF) receptor inhibitor STI571 in chemoresistant glioma cells is associated with enhanced PDGF-BB-mediated signaling and STI571-induced Akt inactivation. J. Cell Phys. (2006) 208:220-228.
   PubMed Web of Science ®Google Scholar
• KILIC T, ALBERTA JA, ZDUNEK PR et al.: Intracranial inhibition of platelet-derived growth factor-mediated glioblastoma cell growth by an orally active kinase inhibitor of the 2-phenlaminopyrimidine class. Cancer Res. (2000) 60(18):5143-5150.
   PubMed Web of Science ®Google Scholar
• GENG L, SHINOHARA ET, KIM D et al.: STI571 (Gleevec) improves tumor growth delay and survival in irradiated mouse models of glioblastoma. Int. J. Radiat. Oncol. Biol. Phys. (2006) 64(1):263-271.
   PubMed Web of Science ®Google Scholar
• WEN PY, YUNG WK, LAMBORN KR et al.: Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08. Clin. Cancer Res. (2006) 12(16):4899-4907.
   PubMed Web of Science ®Google Scholar
• DRESEMANN G: Imatinib and hydroxyurea in pretreated progressive glioblastoma multiforme: a patient series. Ann. Oncol. (2005) 16(10):1702-1708.
   PubMed Web of Science ®Google Scholar
• REARDON DA, EGORIN MJ, QUINN JA et al.: Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme. J. Clin. Oncol. (2005) 23(26):9359-9368.
   PubMed Web of Science ®Google Scholar
• PIETRAS K, OSTMAN A, SJOQUIST M et al.: Inhibition of platelet-derived growth factor receptors reduced interstitial hypertension and increases transcapillary transport in tumors. Cancer Res. (2005) 61(7):2577-2582.
   Google Scholar
• BIHOREL S, CAMENISCH G, GROSS G, LEMAIRE M, SCHERRMANN JM: Influence of hydroxyurea on imatinib mesylate transport at the mouse blood-brain barrier. Drug Metab. Dispos. (2006) Epub ahead of print.
   PubMedGoogle Scholar
• SATHORNSUMETEE S, REARDON DA, QUINN JA et al.: An update on Phase I study of dose-escalating imatinib mesylate plus standard-dosed temozolomide for the treatment of patients with malignant glioma. Proc. Am. Soc. Clin. Oncol. (2006) 24(18S):1560.
   Google Scholar
• VAJKOCZY P, THURNHER A, HIRTH KP et al.: Measuring VEGF-Flk-1 activity and consequences of VEGF-Flk-1 targeting in vivo using intravital microscopy: clinical applications. Oncologist (2000) 5:16-19.
   PubMedGoogle Scholar
• GOLDBRUNNER RH, BENDSZUS M, WOOD J, KIDERLEN M, SASAKI M, TONN JC: PTK787/ZK222584, an inhibitor of vascular endothelial growth factor receptor tyrosine kinases, decreases glioma growth and vascularization. Neurosurgery (2004) 55(2):426-432.
   PubMed Web of Science ®Google Scholar
• FOLKMANN J: What is the evidence that tumors are angiogenesis dependent? J. Natl. Cancer Inst. (1990) 82:4-6.
   PubMed Web of Science ®Google Scholar
• CONRAD C, FRIEDMAN H, REARDON D et al.: A Phase I/II trial of single-agent PTK787/ZK222584 (PTK/ZK), a novel, oral angiogenesis inhibitor, in patients with recurrent glioblastoma multiforme (GBM). Proc. Am. Soc. Clin. Oncol. (2004) 22(110S):1512.
   Web of Science ®Google Scholar
• REARDON D, FRIEDMAN H, YUNG WKA et al.: A Phase I/II trial of PTK787/ZK222584 (PTK/ZK), a novel, oral angiogenesis inhibitor, in combination with either temozolomide or lomustine for patients with recurrent glioblastoma multiforme (GBM). Proc. Am. Soc. Clin. Oncol. (2004) 22(110S):1513.
   Google Scholar
• BASERGA R: The insulin-like growth factor-I receptor as a target for cancer therapy. Expert Opin. Ther. Targets (2005) 9(4):753-768.
   PubMed Web of Science ®Google Scholar
• CHAKRAVARTI A, LOEFFLER JS, DYSON NJ: Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling. Cancer Res. (2002) 62(1):200-207.
   PubMed Web of Science ®Google Scholar
• WANG Y, HAILEY J, WILLIAMS D et al.: Inhibition of insulin-like growth factor-I receptor (IGF-IR) signaling and tumor cell growth by a fully human neutralizing anti-IGF-IR antibody. Mol. Cancer Ther. (2005) 4(8):1214-1221.
   PubMed Web of Science ®Google Scholar
• KOOCHEKPOUR S, JEFFERS M, RULONG S et al.: Met and hepatocyte growth factor/scatter factor expression in human gliomas. Cancer Res. (1997) 57(23):5391-5398.
   PubMed Web of Science ®Google Scholar
• ABOUNADER R, RANGANATHAN S, LAL B et al.: Reversion of human glioblastoma malignancy by U1 small nuclear RNA/ribozyme targeting of scatter factor/hepatocyte growth factor and c-met expression. J. Natl. Cancer Inst. (1999) 91(18):1548-1556.
   PubMed Web of Science ®Google Scholar
• LAL B, XIA S, ABOUNADER R, LATERRA J: Targeting the c-Met pathway potentiates glioblastoma responses to gamma-radiation. Clin. Cancer Res. (2005) 11(12):4479-4486.
   PubMed Web of Science ®Google Scholar
• CAO B, SU Y, OSKARSSON M et al.: Neutralizing monoclonal antibodies to hepatocyte growth factor/scatter factor (HGF/SF) display antitumor activity in animal models. Proc. Natl. Acad. Sci. USA (2001) 98(13):7443-7448.
   PubMed Web of Science ®Google Scholar
• BURGESS T, COXON A, MEYER S et al.: Fully human monoclonal antibodies to hepatocyte growth factor with therapeutic potential against hepatocyte growth factor/c-Met-dependent human tumors. Cancer Res. (2006) 66(3):1721-1729.
   PubMed Web of Science ®Google Scholar
• MARTENS T, SCHMIDT NO, ECKERICH C et al.: A novel one-armed anti-c-met antibody inhibits glioblastoma growth in vivo. Clin. Cancer Res. (2006) 12(20):6144-6152.
   PubMed Web of Science ®Google Scholar
• ADJEI AA, HIDALGO M: Intracellular signal transduction pathway proteins as targets for cancer therapy. J. Clin. Oncol. (2005) 23(23):5386-5403.
   PubMed Web of Science ®Google Scholar
• MARTIN GS: The road to Src. Oncogene (2004) 23:7910-7917.
   PubMed Web of Science ®Google Scholar
• LUND CV, NGUYEN MT, OWENS GC et al.: Reduced glioma infiltration in Src-deficient mice. J. Neurooncol. (2006) 78(1):19-29.
   PubMed Web of Science ®Google Scholar
• RICH JN, HANS C, JONES B et al.: Gene expression profiling and genetic markers in glioblastoma survival. Cancer Res. (2005) 65:4051-4058.
   PubMed Web of Science ®Google Scholar
• TALPAZ M, SHAH NP, KANTARJIAN H et al.: Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N. Engl. J. Med. (2006) 354(24):2531-2541.
   PubMed Web of Science ®Google Scholar
• GUTENBERG A, BRUCK W, BUCHFELDER M, LUDWIG HC: Expression of tyrosine kinases FAK and Pyk2 in 331 human astrocytomas. Acta Neuropathol. (Berl). (2004) 108(3):224-230.
   PubMed Web of Science ®Google Scholar
• HASKELL H, NATARAJAN M, HECKER TP et al.: Focal adhesion kinase is expressed in the angiogenic blood vessels of malignant astrocytic tumors in vivo and promotes capillary tube formation of brain microvascular endothelial cells. Clin. Cancer Res. (2003) 9(6):2157-2165.
   PubMed Web of Science ®Google Scholar
• SHI Q, HJELMELAND AB, KEIR ST et al.: TAE226, a novel low-molecular weight inhibitor of focal adhesion kinase, inhibits glioma growth. Neuro-Oncol. (2006) 8(4):417 (Abstract ET-34).
   Google Scholar
• KNOBBE CB, REIFENBERGER J, REIFENBERGER G: Mutation analysis of the Ras pathway genes NRAS, HRAS, KRAS and BRAF in glioblastomas. Acta Neuropathol. (Berl). (2004) 108(6):467-470.
   PubMed Web of Science ®Google Scholar
• PARSA AT, HOLLAND EC: Cooperative translational control of gene expression by Ras and Akt in cancer. Trends Mol. Med. (2004) 10(12):607-613.
   PubMed Web of Science ®Google Scholar
• SEBOLT-LEOPOLD JS, HERRERA R: Targeting the mitogen-activated protein kinase cascade to treat cancer. Nat. Rev. Cancer (2004) 4(12):937-947.
   PubMed Web of Science ®Google Scholar
• CARAGLIA M, TASSONE P, MARRA M, BUDILLON A, VENUTA S, TAGLIAFERRI P: Targeting Raf-kinase: molecular rationales and translational issues. Ann. Oncol. (2006) 17(Suppl. 7):vii124-vii127.
   PubMed Web of Science ®Google Scholar
• ROUX PP, BLENIS J: ERK and p38 MAPK-activated protein kinases: a family of protein kinases with diverse biological function. Mircobiol. Mol. Biol. Rev. (2004) 68(2):320-344.
   PubMed Web of Science ®Google Scholar
• APPELS NM, BEIJNEN JH, SCHELLENS JH: Development of farnesyl transferase inhibitors: a review. Oncologist (2005) 10(8):565-578.
   PubMed Web of Science ®Google Scholar
• CLOUGHESY TF, KUHN J, ROBINS HI et al.: Phase I trial of tipifarnib in patients with recurrent malignant glioma taking enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study. J. Clin. Oncol. (2005) 23(27):6647-6656.
   PubMed Web of Science ®Google Scholar
• CLOUGHESY TF, WEN PY, ROBINS HI et al.: Phase II trial of tipifarnib in patients with recurrent malignant glioma either receiving or not receiving enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study. J. Clin. Oncol. (2006) 24(22):3651-3656.
   PubMed Web of Science ®Google Scholar
• SATHORNSUMETEE S, HJELMELAND AB, KEIR ST et al.: AAL881, a novel small molecule inhibitor of RAF and vascular endothelial growth factor receptor activities, blocks growth of malignant glioma. Cancer Res. (2006) 66(17):8722-8730.
   PubMed Web of Science ®Google Scholar
• NEWTON HB: Molecular neuro-oncology and development of targeted therapeutic strategies for brain tumors. Part 2: PI3K/Akt/PTEN, mTOR, SHH/PTCH and angiogenesis. Expert Rev. Anti-Cancer Ther. (2004) 4(1):105-128.
   PubMedGoogle Scholar
• BADER AG, KANG S, ZHAO L, VOGT PK: Oncogenic PI3K deregulates transcription and translation. Nat. Rev. Cancer (2005) 5(12):921-929.
   PubMed Web of Science ®Google Scholar
• CHAKRAVARTI A, ZHAI G, SUZUKI Y et al.: The prognostic significance of phosphatidylinositol 3-kinase pathway activation in human gliomas. J. Clin. Oncol. (2004) 22(10):1926-1933.
   PubMed Web of Science ®Google Scholar
• HAAS-KOGAN D, SHALEV N, WONG M, MILLS G, YOUNT G, STOKOE D: Protein kinase B (PKB/Akt) activity is elevated in glioblastoma cells due to mutation of the tumor suppressor PTEN/MMAC. Curr. Biol. (1998) 8(21):1195-1198.
   PubMed Web of Science ®Google Scholar
• KANDEL ES, SKEEN J, MAJEWSKI N et al.: Activation of Akt/protein kinase B overcomes a G2/M cell cycle checkpoint induced by DNA damage. Mol. Cell. Biol. (2002) 22(22):7831-7841.
   PubMed Web of Science ®Google Scholar
• SHAW RJ, CANTLEY LC: Ras, PI(3)K, and mTOR signalling controls tumor cell growth. Nature (2006) 441:424-430.
   PubMed Web of Science ®Google Scholar
• MITA MM, MITA A, ROWINSKY EK et al.: The molecular target of rapamycin (mTOR) as a therapeutic target against cancer. Cancer Biol. Ther. (2003) 2(4 Suppl. 1):S169-S177.
   PubMed Web of Science ®Google Scholar
• MOMOTA H, NERIO E, HOLLAND EC: Perifosine inhibits multiple signaling pathways in glial progenitors and cooperates with temozolomide to arrest cell proliferation in gliomas in vivo. Cancer Res. (2005) 65(16):7429-7435.
   PubMed Web of Science ®Google Scholar
• GALANIS E, BUCKNER JC, MAURER MJ et al.: Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Carolina Cancer Treatment Group Study. J. Clin. Oncol. (2005) 23(23):5294-5304.
   PubMed Web of Science ®Google Scholar
• CHANG SM, WEN P, CLOUGHESY T et al.: Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme. Invest. New Drugs (2005) 23(4):357-361.
   PubMed Web of Science ®Google Scholar
• IWAMARU A, KONDO Y, IWADO E et al.: Silencing mammalian target of rapamycin signaling by small interfering RNA enhances rapamycin-induced autophagy in malignant glioma cells. Oncogene (2006) Epub ahead of print.
   Google Scholar
• THOMAS GV, TRAN C, MELLINGHOFF IK et al.: Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer. Nat. Med. (2006) 12(1):122-127.
   PubMed Web of Science ®Google Scholar
• OKHRIMENKO H, LU W, XIANG C, HAMBURGER N, KAZIMIRSKY G, BRODIE C: Protein kinase C-ε regulates the apoptosis and survival of glioma cells. Cancer Res. (2005) 65(16):7301-7309.
   PubMed Web of Science ®Google Scholar
• DA ROCHA AB, MANS DR, REGNER A, SCHWARTSMANN G: Targeting protein kinase C: new therapeutic opportunities against high-grade malignant gliomas? Oncologist (2002) 7(1):17-33.
   PubMed Web of Science ®Google Scholar
• NISHIZUKA Y: The molecular heterogeneity of protein kinase C and its implications for cellular regulation. Nature (1988) 334(6184):661-665.
   PubMed Web of Science ®Google Scholar
• GRAFF JR, MCNULTY AM, HANNA KR et al.: The protein kinase Cβ-selective inhibitor, enzastaurin (LY317613.HCI), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts. Cancer Res. (2005) 65(16):7462-7469.
   PubMed Web of Science ®Google Scholar
• HUI AM, ZHANG W, CHEN W et al.: Agents with selective estrogen receptor (ER) modulator activity induce apoptosis in vitro and in vivo in ER-negative glioma cells. Cancer Res. (2004) 64(24):9115-9123.
   PubMed Web of Science ®Google Scholar
• CHAMBERLAIN MC, KORMANIK PA: Salvage chemotherapy with tamoxifen for recurrent anaplastic astrocytomas. Arch. Neurol. (1999) 56(6):703-708.
   PubMed Web of Science ®Google Scholar
• BRANDES AA, ERMANI M, TURAZZI S et al.: Procarbazine and high-dose tamoxifen as a second-line regimen in recurrent high-grade gliomas: a Phase II study. J. Clin. Oncol. (1999) 17(2):645-650.
   PubMed Web of Science ®Google Scholar
• SPENCE AM, PETERSON RA, SCHARNHORST JD, SILBERGELD DL, ROSTOMILY RC: Phase II study of concurrent continuous Temozolomide (TMZ) and Tamoxifen (TMZ) for recurrent malignant astrocytic gliomas. J. Neurooncol. (2004) 70(1):91-95.
   PubMed Web of Science ®Google Scholar
• FINE HA, KIM L, ROYCE C et al.: Results from Phase II trial of enzastaurin (LY317615) in patients with recurrent high grade gliomas. Proc. Am. Soc. Clin. Oncol. (2005) 23(Suppl. 115S):1504.
   Google Scholar
• DRUKER B, TALPAZ M, RESTA DJ et al.: Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med. (2001) 344(14):1031-1037.
   PubMed Web of Science ®Google Scholar
• RICH JN, SATHORNSUMETEE S, KEIR ST et al.: ZD6474, a novel tyrosine kinase inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor, inhibits tumor growth of multiple nervous system tumors. Clin. Cancer Res. (2005) 11(22):8145-8157.
   PubMed Web of Science ®Google Scholar
• SCHUENEMAN AJ, HIMMELFARB E, GENG L et al.: SU11248 maintenance therapy prevents tumor regrowth after fractionated irradiation of murine tumor models. Cancer Res. (2003) 63(14):4009-4016.
   PubMed Web of Science ®Google Scholar
• FAIVRE S, DELBALDO C, VERA K et al.: Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J. Clin. Oncol. (2006) 24(1):25-35.
   PubMed Web of Science ®Google Scholar
• BURRIS HA III, HURWITZ HI, DEES EC et al.: Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. J. Clin. Oncol. (2005) 23(23):5305-5313.
   PubMed Web of Science ®Google Scholar
• JONES-BOLIN S, ZHAO H, HUNTER K, KLEIN-SZANTO A, RUGGERI B: The effects of the oral, pan-VEGF-R kinase inhibitor CEP-7055 and chemotherapy in orthotopic models of glioblastoma and colon carcinoma in mice. Mol. Cancer Ther. (2006) 5(7):1744-1753.
   PubMed Web of Science ®Google Scholar
• POLVERINO A, COXON A, STARNES C et al.: AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts. Cancer Res. (2006) 66(17):8715-8721.
   PubMed Web of Science ®Google Scholar
• ALBERT DH, TAPANG P, MAGOC TJ et al.: Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor. Mol. Cancer Ther. (2006) 5(4):995-1006.
   PubMed Web of Science ®Google Scholar
• FAN QW, KNIGHT ZA, GOLDENBERG DD et al.: A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma. Cancer Cell. (2006) 9(5):341-349.
   PubMed Web of Science ®Google Scholar
• LI B, CHANG CM, YUAN M, MCKENNA WG, SHU HK: Resistance to small molecule inhibitors of epidermal growth factor receptor in malignant gliomas. Cancer Res. (2003) 63(21):7443-7450.
   PubMed Web of Science ®Google Scholar
• O’REILLY KE, ROJO F, SHE QB et al.: mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res. (2006) 66(3):1500-1508.
   PubMed Web of Science ®Google Scholar
• HUANG S, ARMSTRONG EA, BENAVENTE S, CHINNAIVAN P, HARARI PM: Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor. Cancer Res. (2004) 64(15):5355-5362.
   PubMed Web of Science ®Google Scholar
• GOUDAR RK, SHI Q, HJELMELAND MD et al.: Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2(AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition. Mol. Cancer Ther. (2005) 4(1):101-112.
   PubMed Web of Science ®Google Scholar
• RAO RD, MLADEK AC, LAMONT JD et al.: Disruption of parallel and converging signaling pathways contributes to the synergistic antitumor effects of simultaneous mTOR and EGFR inhibition in GBM cells. Neoplasia (2005) 7(10):921-929.
   PubMed Web of Science ®Google Scholar
• WANG MY, LU KV, ZHU S et al.: Mammalian target of rapamycin Inhibition promotes response to epidermal growth factor receptor kinase inhibitors in PTEN-deficient and PTEN-intact glioblastoma cells. Cancer Res. (2006) 66(16):7864-7869.
   PubMed Web of Science ®Google Scholar
• REARDON DA, QUINN JA, VREDENBURGH JJ et al.: Phase I trial of gefitinib plus sirolimus in adults with recurrent malignant glioma. Clin. Cancer Res. (2006) 12(3 Pt 1):860-868.
   PubMed Web of Science ®Google Scholar
• DOHERTY L, GIGAS DC, KESARI S et al.: Pilot study of the combination of EGFR and mTOR inhibitors in recurrent malignant gliomas. Neurology (2006) 67(1):156-158.
   PubMed Web of Science ®Google Scholar
• EDWARDS LA, VERREAULT M, THIESSEN B et al.: Combined inhibition of the phosphatidylinositol 3-kinase/Akt and Ras/mitogen-activated protein kinase pathways results in synergistic effects in glioblastoma cells. Mol. Cancer Ther. (2006) 5(3):645-654.
   PubMed Web of Science ®Google Scholar
• JANE EP, PREMKUMAR DR, POLLACK IF: Coadministration of sorafenib with rottlerin potently inhibits cell proliferation and migration in human malignant glioma cells. J. Pharmacol. Exp. Ther. (2006) Epub ahead of print.
   PubMedGoogle Scholar
• YU C, FRIDAY BB, LAI JP et al.: Cytotoxic synergy between the multikinase inhibitor sorafenib and the proteasome inhibitor bortezomib in vitro: induction of apoptosis through Akt and c-Jun NH2-terminal kinase pathways. Mol. Cancer Ther. (2006) 5(9):2378-2387.
   PubMed Web of Science ®Google Scholar
• MANI A, GELMANN EP: The ubiquitin-proteasome pathway and its role in cancer. J. Clin. Oncol. (2005) 23:4776-4789.
   PubMed Web of Science ®Google Scholar
• PHUPHANICH S, SUPKO J, CARSON KA et al.: Phase I trial of bortezomib in adults with malignant glioma. Proc. Am. Soc. Clin. Oncol. (2006) 24(18S):1567.
   Google Scholar
• PREMKUMAR DR, ARNOLD B, JANE EP, POLLACK IF: Synergistic interaction between 17-AAG and phosphatidylinositol 3-kinase inhibition in human malignant glioma cells. Mol. Carcinog. (2006) 45(1):47-59.
   PubMed Web of Science ®Google Scholar
• RICHTER K, BUCKNER J: Hsp90: chaperoning signal transduction. J. Cell. Physiol. (2001) 188:281-290.
   PubMed Web of Science ®Google Scholar
• PRADOS M, YUNG W, WEN P et al.: Phase I study of ZD1839 plus temozolomide in patients with malignant glioma. A study of the North American Brain Tumor Consortium. Proc. Am. Soc. Clin. Oncol. (2004) 22(14):1504.
   Google Scholar
• DAMIANO V, MELISI D, BIANCO C et al.: Cooperative antitumor effect of multitargeted kinase inhibitor ZD6474 and ionizing radiation in glioblastoma. Clin. Cancer Res. (2005) 11(15):5639-5644.
   PubMed Web of Science ®Google Scholar
• SARKARIA JN, CARLSON BL, SCHROEDER MA et al.: Use of an orthotopic xenograft model for assessing the effect of epidermal growth factor receptor amplification on glioblastoma radiation response. Clin. Cancer Res.. (2006) 12(7 Pt 1):2264-2271.
   PubMed Web of Science ®Google Scholar
• KRISHNAN S, BROWN PD, BALLMAN KY et al.: Phase I trial of erlotinib with radiation therapy in patients with glioblastoma multiforme: results of North Central Cancer Treatment Group protocol N0177. Int. J. Radiat. Oncol. Biol. Phys. (2006) 65(4):1192-1199.
   PubMed Web of Science ®Google Scholar
• VREDENBURGH J, DESJARDINS A, HERNDON JE et al.: Bevacizumab, a monoclonal antibody to vascular endothelial growth factor (VEGF), and irinotecan for treatment of malignant gliomas. Proc. Am. Soc. Clin. Oncol. (2006) 24(18S):1506.
   Google Scholar
• IMAI K, TAKAOKA A: Comparing antibody and small-molecule therapies for cancer. Nat. Rev. Cancer (2006) 6:717-727.
   Google Scholar
• HEINRICH MC, CORLESS CL, DEMETRI GD et al.: Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J. Clin. Oncol. (2003) 21(23):4342-4349.
   PubMed Web of Science ®Google Scholar
• SLAMON DJ, LEYLAND-JONES B, SHAK S et al.: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. (2001) 344(11):783-792.
   PubMed Web of Science ®Google Scholar
• DRUKER BJ: Circumventing resistance to kinase-inhibitor therapy. N. Engl. J. Med. (2006) 354(24):2594-2596.
   PubMed Web of Science ®Google Scholar
• KANTARJIAN H, GILES F, WUNDERLE L et al.: Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N. Engl. J. Med. (2006) 354(24):2542-2551.
   PubMed Web of Science ®Google Scholar
• DANCEY JE, CHEN HX: Strategies for optimizing combinations of molecularly targeted anticancer agents. Nat. Rev. Drug Discov. (2006) 5:649-659.
   PubMed Web of Science ®Google Scholar
• BILD AH, POTTI A, NEVINS JR: Linking oncogenic pathways with therapeutic opportunities. Nat. Rev. Cancer (2006) 6(9):735-741.
   PubMed Web of Science ®Google Scholar
• HATANO M, EGUCHI J, TATSUMI T et al.: EphA2 as a glioma-associated antigen: a novel target for glioma vaccines. Neoplasia (2005) 7(8):717-722.
   PubMed Web of Science ®Google Scholar
• NAKADA M, DRAKE KL, NAKADA S, NISKA JA, BEREN ME: Ephrin-B3 ligand promotes glioma invasion through activation of Rac1. Cancer Res. (2006) 66(17):8492-500.
   PubMed Web of Science ®Google Scholar
• LIPINSKI CA, TRAN NL, MENASHI E et al.: The tyrosine kinase pyk2 promotes migration and invasion of glioma cells. Neoplasia (2005) 7(5):435-445.
   PubMed Web of Science ®Google Scholar
• HJELMELAND MD, HJELMELAND AB, SATHORNSUMETEE S et al.: SB-431542, a small molecule transforming growth factor-beta-receptor antagonist, inhibits human glioma cell line proliferation and motility. Mol. Cancer Ther. (2004) 3(6):737-745.
   PubMed Web of Science ®Google Scholar
• UHL M, AULWURM S, WISCHHUSEN J et al.: SD-208, a novel transforming growth factor beta receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo. Cancer Res. (2004) 64(21):7954-7961.
   PubMed Web of Science ®Google Scholar
• DIETZMANN K, KIRCHES E, VON BOSSANYI, JACHAU K, MAWRIN C: Increased human polo-like kinase-1 expression in gliomas. J. Neurooncol. (2001) 53(1):1-11.
   PubMed Web of Science ®Google Scholar
• NEWCOMB EW, ALI MA, SCHNEE T et al.: Flavopiridol downregulates hypoxia-mediated hypoxia-inducible factor-1alpha expression in human glioma cells by a proteasome-independent pathway: implications for in vivo therapy. Neuro-oncol. (2005) 7(3):225-235.
   PubMed Web of Science ®Google Scholar
• LASSMAN AB, ABREY LE, GILBERT MR: Response of glioblastomas to EGFR kinase inhibitors. N. Engl. J. Med. (2006) 354(5):525-526.
   PubMedGoogle Scholar
• WEN PY, KESARI S, DRAPPATZ J: Malignant gliomas: strategies to increase the effectiveness of targeted molecular treatment. Expert Rev. Anti-Cancer Ther. (2006) 6(5):733-754.
   PubMed Web of Science ®Google Scholar
• BREEDVELD P, PLUIM D, CIPRIANI G et al.: The effect of Bcrp1 (Abcg2) on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (Gleevec): implications for the use of breast cancer resistance protein and P-glycoprotein inhibitors to enable the brain penetration of imatinib in patients. Cancer Res. (2005) 65(7):2577-2582.
   PubMed Web of Science ®Google Scholar
• JAIN RK: Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science (2005) 307(5706):58-62.
   PubMed Web of Science ®Google Scholar
• KERKELA R, GRAZETTE L, YACOBI R et al.: Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat. Med. (2006) 12(8):908-916.
   PubMed Web of Science ®Google Scholar